Prior Radiotherapy Improves Progression-free Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Tremelimumab–Durvalumab
Prior radiotherapy improves PFS in patients treated with tremelimumab-durvalumab for advanced HCC. The abscopal effect and up-regulation of immune mechanisms may contribute to improved outcomes.
Authors
- Kenta Motomura (ORCID: https://orcid.org/0000-0002-7515-099X)
- Hideo Suzuki (ORCID: https://orcid.org/0000-0002-1469-7449)
- Kazuki Kurosaka
- Masayoshi Yada (ORCID: https://orcid.org/0000-0002-1129-5380)
- Akifumi Kuwano (ORCID: https://orcid.org/0000-0001-9397-8056)
- Yoshihiro Ohishi
- T. Sasaki (ORCID: https://orcid.org/0000-0001-5456-7801)
- Takao Hamamoto (ORCID: https://orcid.org/0000-0001-9728-1264)
- Masatake Tanaka (ORCID: https://orcid.org/0000-0001-7461-0678)
Institutions
- Ichinomiya Kenshin College (JP)
- Aso Iizuka Hospital (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-11-29
- DOI
- https://doi.org/10.21873/anticanres.17903
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32